Cargando…

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab

AIM: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. RESULTS: Alemtuzumab–Alexa Fl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Liaqat, Saxena, Gauri, Jones, Meleri, Leisegang, Georgia R, Gammon, Luke, Gnanapavan, Sharmilee, Giovannoni, Gavin, Schmierer, Klaus, Baker, David, Kang, Angray S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2020
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177201/ https://www.ncbi.nlm.nih.gov/pubmed/32096651 http://dx.doi.org/10.2144/btn-2019-0122

Ejemplares similares

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
por: Baker, David, et al.
Publicado: (2020)

Detecting and predicting neutralization of alemtuzumab responses in MS
por: Saxena, Gauri, et al.
Publicado: (2020)

GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains
por: Saxena, Gauri K., et al.
Publicado: (2020)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
por: Baker, David, et al.
Publicado: (2020)

A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann’s syndrome
por: Gnanapavan, Sharmilee, et al.
Publicado: (2014)

The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
por: Baker, David, et al.
Publicado: (2023)

No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation
por: Keddie, Stephen, et al.
Publicado: (2018)

CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
por: Reyes, Saúl, et al.
Publicado: (2020)

Both cladribine and alemtuzumab may effect MS via B-cell depletion
por: Baker, David, et al.
Publicado: (2017)

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
por: Allen-Philbey, Kimberley, et al.
Publicado: (2023)

The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis
por: Adams, Ashok, et al.
Publicado: (2022)

The Evolution of Neurofilament Light Chain in Multiple Sclerosis
por: Ferreira-Atuesta, Carolina, et al.
Publicado: (2021)

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
por: Baker, David, et al.
Publicado: (2017)

Progression in multiple sclerosis is associated with low endogenous NCAM
por: Gnanapavan, Sharmilee, et al.
Publicado: (2013)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis
por: von Kutzleben, Stephanie, et al.
Publicado: (2017)

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis
por: Tallantyre, Emma C, et al.
Publicado: (2022)

Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β
por: Lee, Paul R., et al.
Publicado: (2017)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy
por: Mahler, Christoph, et al.
Publicado: (2020)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
por: Jia, Yan, et al.
Publicado: (2012)

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2021)

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression
por: Gnanapavan, Sharmilee, et al.
Publicado: (2013)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Failure of alemtuzumab therapy in three patients with MOG antibody associated disease
por: Seneviratne, Sinali O., et al.
Publicado: (2022)

COVID‐19 Vaccine Response in People with Multiple Sclerosis
por: Tallantyre, Emma C., et al.
Publicado: (2021)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
por: Arnold, Douglas L., et al.
Publicado: (2016)

Development of an in Vitro Potency Assay for Anti-anthrax Lethal Toxin Neutralizing Antibodies
por: Whiting, Gail, et al.
Publicado: (2012)

Alemtuzumab in the up-front setting
por: Kaufman, Matthew, et al.
Publicado: (2008)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
por: Coles, Alasdair J., et al.
Publicado: (2017)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary
por: Schmierer, K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r32i9de3k745drm8hf1em7fkc8